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The aim of this retrospective study was to assess respiratory and cardiac function in a large cohort of patients with congenital
muscular dystrophies (CMD) with reduced glycosylation of alphadystroglycan (a-DG). Thirteen of the 115 patients included in the study
died between the age of 1 month and 20 years. The age at last follow up of the surviving 102 ranged between 1 year and 68 years (median:
9.3 years). Cardiac involvement was found in 7 of the 115 (6%), 5 with dilated cardiomyopathy, 1 cardiac conductions defects and 1
mitral regurgitation. Respiratory function was impaired in 14 (12%). Ten of the 14 required non invasive nocturnal respiratory support,
while the other four required invasive ventilation. Cardiac or respiratory involvement was found in patients with mutations in FKRP,
POMT1, POMT2. All of the patients in whom mutation in POMGnT1 were identiﬁed had normal cardiac and respiratory function.
Published by Elsevier B.V.
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The term “dystroglycanopathies” has been used to
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Open access under CC BY-NC-ND license.ders with a muscle biopsy showing dystrophic features and
a reduction of a-dystroglycan (a-DG) with frequently asso-
ciated central nervous system involvement [1].
The spectrum of clinical phenotypes ranges from the
severe Walker–Warburg syndrome (WWS), muscle–eye–
brain disease (MEB) and Fukuyama congenital muscular
dystrophy (FCMD), all with severe muscle, eye and brain
involvement, to mild cases of limb girdle muscular dystro-
phies with late onset and no brain or eye involvement.
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found associated with mutations in six genes coding for
putative and demonstrated glycosyltransferases or acces-
sory proteins of glycosyltransferases : Protein-O-mannosyl
transferase 1 (POMT1; OMIM 607423), Protein-O-manno-
syl transferase 2 (POMT2; OMIM 607439), Protein-O-
mannose 1,2-N-acetylglucosaminyltransferase 1 (POM-
GnT1; OMIM 606822), fukutin (FKTN; OMIM 607440),
Fukutin-related protein (FKRP; OMIM 606596) and
LARGE (OMIM 603590) [2–7]. Recent suggestions that
congenital muscular dystrophy (CMD) secondary to
decreased a-dystroglycan expression may also be found
associated with N-glycosylation disorders or mutations in
dystroglycan itself are still limited to single cases [8].
Patients with dystroglycanopathies have common fea-
tures, such as predominant involvement of the upper limbs
and elevated CK but the spectrum of clinical severity ranges
from the severe WWS, MEB and FCMD with severe struc-
tural muscle, eye and brain involvement, tomilder cases with
late onset and no brain or eye involvement.
Two studies on large cohorts have demonstrated that
mutations in individual genes can be associated with diﬀer-
ent phenotypes and that, conversely, the same phenotype
can be found in association with diﬀerent known genes.
[9,10]. Approximately half of the dystroglycanopathy
patients do not have mutations in the known genes, this
suggesting further genetic heterogeneity [9,10]. Patients
with unknown mutations often have similar phenotypes
to the cases in whom mutations have been identiﬁed, these
ﬁndings strongly suggesting that the identity of the defec-
tive gene (or the absence of mutations in the known genes)
cannot be predicted from the clinical phenotype.
All the previous studies reporting phenotypes in patients
with known and unknown mutations have mainly focused
on brain and eye involvement and maximal functional abil-
ity while little has been reported about other clinical
aspects, such as severity of cardiac or respiratory involve-
ment, which are common in other forms of congenital mus-
cular dystrophy [11,12].
The aim of this retrospective study was to review respi-
ratory and cardiac data in a large cohort of patients with
CMD and reduction of alpha dystroglycan and their rela-
tionship with genetic and brain MRI ﬁndings.
2. Patients and methods
2.1. Patients
All patients had a diagnosis of CMD with a-DG deﬁ-
ciency. Inclusion criteria were early presentation (neonatal
or delayed acquisition early milestones), myopathic/dystro-
phic changes on muscle biopsy, and deﬁciency of a-DG on
the sarcolemma of skeletal muscle ﬁbers [13,14].
Because of the possible overlap with early onset limb
girdle muscular dystrophies, it has recently been suggested
that CMD should include cases with onset of weakness pre-
natally or within the ﬁrst months of life, before ambulationis acquired. LGMD in contrast, would include the cases
with onset after ambulation has been acquired.
All the patients included in this study had already been
included in two previous large multicentric studies report-
ing muscle, eye and brain involvement and motor abilities.
Details of the cohorts and of their genetic background,
including methodology in genetic screening have already
been reported [9,10]. We limited this study to those patients
who had been seen at least once at one of the participating
centers and in whom there was at least one assessment of
cardiac and respiratory function.2.2. Clinical data
Data were collected retrospectively using a structured
proforma, noting information from overnight oximetry
sleep studies and, when available, forced vital capacity
(FVC) and cardiac function studies including electrocardi-
ography (ECG) and echocardiogram results.
Echocardiogram was deﬁned as abnormal if there were
congenital abnormalities, signs of dilated cardiomyopathy
or of decreased left ventricular systolic function.3. Results
One hundred and ﬁfteen patients fulﬁlled the inclusion
criteria. Thirteen of the 115 died between 1 month and
20 years. The age at last follow up of the surviving 102 ran-
ged between 1 year and 68 years (median: 9.3 years).
All data were analyzed subdividing the respiratory and
cardiac function according to genetic ﬁndings and to the
classiﬁcation of phenotypes based on MRI and cognitive
ﬁndings [9,10].3.1. Cardiac function
Only 7 of the 115 had signs of cardiac involvement, 5
had dilated cardiomyopathy, one had mitral valve regurgi-
tation and one mild conduction defects. There was no spe-
ciﬁc association between mutations or clinical phenotypes
and cardiac function (Tables 1–3). On echocardiography
another child was found to have aortic coartation but no
ECG or echocardiogram abnormality.3.2. Respiratory function
All patients had at least one measurement of overnight
oxygen saturation. Fourteen of the 115 (12%) required ven-
tilator support at the time of this study. Ten of these 14
patients had signs of nocturnal hypoventilation and were
started on non invasive respiratory support, while the other
four required tracheostomy due to acute respiratory dis-
tress. Table 1 shows details of the patients with respiratory
impairment. There was no speciﬁc correlation between
mutations or clinical phenotypes and respiratory function
(Tables 2 and 3).
Table 1
Individual details of patients with abnormal cardiac or respiratory ﬁndings.
Patient Mutation Brain MRI Non invasive
ventilation/age
Tracheostomy/age Cardiac involvement Age at onset Age follow up Age at death
1 FKRP Normal – – DCM 4 years – 6 years
2 FKRP MEB – – DCM 2 years 4 years –
3 FKRP Normal – – DCM 4 years 7 years –
4 POMT1 Normal – – DCM 19 years 20 years –
5 POMT2 MEB – – DCM –
6 Negative Atrophy – – Conductions defects 58 years 68 years –
7 Negative Normal – – Mitral regurgitation 12 years 14 years –
8 Negative Normal Neonatal – – – 5 years –
9 Negative MEB Neonatal – – – – 1 month
10 Negative Atrophy Neonatal – – – 10 years –
11 Negative Normal Neonatal – – – 9 years –
12 FKRP White matter 6 months – – – 8 years –
13 FKRP Normal 9 years – – – 10 years –
14 FKRP Normal 13 years – – – 14 years –
15 POMT2 Hydrocephalus 19 years – – – – 20 years
16 Negative White matter 20 years – – – 21 years
17 Negative Cerebellar – Neonatal – – 6 years
18 POMT2 Cerebellar – 3 years – – 13 years
19 Negative Cerebellar – 4 years – – – 6 years
20 Negative Cerebellar – – – – – 7 months
21 Negative Cerebellar – – – – – 16 months
22 Negative Cerebellar – – – – – 13 years
23 POMT2 Cerebellar – 7 years – – – 12 years
24 POMGnT1 MEB neonatal
25 POMT1 WWS – – – – – 4 years
26 POMT2 WWS Neonatal
27 Negative WWS Neonatal
28 Negative WWS Neonatal
MEB, muscle eye brain disease; WWS, Walker Warburg syndrome; DCM, dilated cardiomyopathy.
Table 2
Genetic and clinical ﬁndings.
Abnormal cardiac function Respiratory failure Death
FKRP (n = 13) 3/13 (23%) 3/13 (23%) 1/13 (7.6%)
POMT1 (n = 14) 1/14 (7 %) 1/14 (7%) 1/14 (7%)
POMT2 (n = 10) 1/10 (1%) 3/10 (3%) 3/10 (3%)
POMGNT1 (n = 18) 0/18 0/18 1/18 (5.5%)
LARGE (n = 2) 0/2 0/2 0/2
FKTN (n = 1) 0/1 0/1 0/1
All negative (n = 57) 2/57 (3.5%) 7/57 (12%) 7/57(12%)
Table 3
Brain MRI and clinical ﬁndings.
Abnormal cardiac
function
Respiratory
failure
Death
Normal brain MRI, no mental retardation (n = 8) 3/8 (37.5%) 2/8 (25%) 1/8 (12.5%)
Normal brain MRI, mental retardation (n = 26) 1/26 (3.8%) 3/26 (11.5%) 0/26
Cerebellar involvement (n = 20) 0/20 4/20 (20%) 5/20 (25%)
MEB (n = 35) 2/35 (5.7%) 1/35 (2.8%) 2/35 (5.7%)
WWS (n = 8) 0/8 0/8 4/8 (50%)
Hydrocephalus/Chiari (n = 7) 0/7 1/7 (14%) 1/7 (14%)
Brain atrophy (n = 5) 1/5 (20%) 1/5 (20%) 0/5
White matter (n = 6) 0/6 2/6 (33%) 0/6
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the patients due to young age, lack of collaboration sec-ondary to mental retardation, or macroglossia or
malocclusion.
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Thirteen patients died, four from intractable seizures
and the other nine for severe acute events leading to respi-
ratory failure (Tables 1–3). No postmortem was performed
to ascertain causes of death.
4. Discussion
The aim of this retrospective study was to assess cardiac
and respiratory function in a large cohort of patients with
CMD and reduction of a-dystroglycan on muscle biopsy.
Cardiac function was found to be impaired in only 7 of
the 115 children. These patients carried mutations in
FKRP, POMT1 and POMT2. One patient with LARGE
mutations had an aortic coartation but no signs of primary
cardiac involvement.
Cardiac abnormalities have already been reported in
CMD patients with dystroglycanopathies [15–18], mainly
associated with FKRP and fukutin mutations. In particu-
lar, dilated cardiomyopathy has been found to occur fre-
quently in patients with FKRP mutations and LGMD2I
phenotype [19–22] but has also been reported in ﬁve cases
of patients with CMD phenotype [15,23–25]. In our cohort
including only CMD patients, cardiac involvement was
found in 3 of the 13 patients with FKRP mutations, two
of whom had already been reported [15].
We also found dilated cardiomyopathy in a patient car-
rying POMT2 mutation and in one patient with POMT1
mutations. To our knowledge, with the exception of a
report of left ventricular hypertrophy in a patient with
POMT2 mutations [18], this is the ﬁrst report of cardiac
involvement in patients with CMD due to POMT1 and
POMT2 mutations.
As we only had one patient with FKTN mutations and
two with LARGE mutations we cannot draw any conclu-
sion on possible cardiac involvement that has been previ-
ously reported to be frequent in patients with CMD and
FKTN mutations in Japan [17].
Cardiac involvement appeared to occur infrequently in
the groups without mutations in the known genes. Only
one patient developed conduction defects at the age of
58 years.
Our ﬁndings conﬁrm previous observations that cardiac
impairment is relatively rare in this group of disorders.
When found, cardiac abnormalities were already present
before 12 years of age in 4 of the 7 cases. We believe that
the low detection rate cannot be attributed to the age of
the patients studied as more than 35% of our cohort was
above the age of 12 and, in 5 cases, above the age of
20 years at the time of the study.
Impairment of respiratory function was also not com-
mon, occurring in only 14 of the 115 (12%) patients. Unfor-
tunately, because of age, limited cooperation, mental
retardation and in a number of cases, macroglossia or
malocclusion, the majority of patients did not have reliable
measurements of FVC and we cannot provide an estimateof their values according to age. Sleep studies however were
available in all patients studied, with 14 patients requiring
ventilator support. Four of the 14 required invasive venti-
lation, inserted following an acute episode of respiratory
distress. The other 10 had abnormal sleep studies which
prompted the initiation of non invasive nocturnal ventila-
tion. In 6 of the 10 ventilation was required before the
age of one year.
Overall respiratory problems were also not frequent and
not speciﬁcally associated with any of the known dystrogly-
canopathy genes or individual phenotypes even though
they were relatively more common in the patients with
FKRP mutations, with normal brain MRI ﬁndings and
no mental retardation, in those with POMT1 and POMT2
mutations with cerebellar involvement, microcephaly and
mental retardation, and in a recently reported subgroup
of CMD patients with severe intractable epilepsy [25].
The group with intractable epilepsy was also at higher risk
of reduced survival as 4 of the 13 patients who died
belonged to this subgroup.
In the large group of patients with POMGnT1 muta-
tions respiratory and cardiac impairment, never occurred
even though one patient with MEB phenotype and POM-
GnT1 mutations died in the ﬁrst year for acute events.
Unlike other aspects of phenotype that are related to the
severity of the mutations in the dystroglycanopathies,
respiratory and cardiac function abnormalities were not
speciﬁcally associated with the more severe MEB or
WWS phenotypes, typically associated with mutations
leading to severe functional defects (e.g., involvement of
residues crucial for the enzymatic activity or those leading
to frameshift and prematurely truncated protein) resulting
in the severe brain, eye and muscle involvement. While
these patients appear to be at higher risk of acute fatal
events, those who survive early childhood do not demon-
strate evidence of chronic progressive cardiac or respira-
tory impairment. In our cohort 4 of the 8 patients with
WWS and 2 of the 35 with MEB died within the ﬁrst years
of life but none of the surviving patients with WWS pheno-
type and only 2 of the 33 surviving MEB patients had car-
diac abnormalities or progressive respiratory failure. These
data are in agreement with previous limited studies also
reporting that cardiac abnormalities are not frequent in
WWS or MEB patients [12,26–28]. Since none of the
patients who died in our series had autopsy studies, the
causes of death were not always entirely clear and for this
reason they were described separately. In two patients who
died from acute cardiorespiratory complications, assess-
ments performed months preceding death had been
reported as normal this suggesting that death may occur
due to severe acute cardiorespiratory events in fragile
patients who often also have bulbar weakness.
One of the advantages of this study is that includes the
largest cohort of CMD patients with dystroglycanopathy
reported so far in the literature. The study was only possi-
ble because two large networks provided their retrospective
data but this has limited the possibility to obtain more
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Although the information collected are enough to exclude
that severe signs of cardiac and respiratory impairment
are common features in this cohort, prospective longitudi-
nal studies are still needed to obtain more detailed informa-
tion on the onset and the possible changes of cardiac and
respiratory function over time. As many of the patients
reported in this study were in the pediatric age, a longer fol-
low up will also help to establish if some of them will
develop cardiac and respiratory problems at a later age.
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